Noticias y vídeos - IMMUNOVIA AB - Inglés

Immunovia publishes the Annual Report for 2024 PR Newswire LUND, Sweden, April 2, 2025 LUND, Sweden , April 2, 2025 /PRNewswire/ -- Immunovia AB (publ) today announced that the Annual Report for 2024 has been published. The annual report can be downloaded in pdf format and is available on Immunovia's website. For more information, please contact: Jeff Borcherding CEO and President [email protected] Immunovia in brief Immunovia AB (IMMNOV: Nasdaq Stockholm), is a diagnostic company...

The exercise period for warrants series TO 3 begins today PR Newswire LUND, Sweden, April 1, 2025 LUND, Sweden , April 1, 2025 /PRNewswire/ -- Today, 1 April 2025 , the exercise period for warrants series TO 3 in Immunovia AB (publ) ("Immunovia" or the "Company") (the "Warrant Programme") begins. The exercise period runs until 15 April 2025 . Summarized terms for the warrants of series TO 3 Structure : One (1) warrant series TO 3 entitles the holder to subscribe for one (1) new share in the...

Immunovia announces determined exercise price for warrants series TO 3 PR Newswire LUND, Sweden, March 27, 2025 LUND, Sweden , March 27, 2025 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that the exercise price for warrants series TO 3 (the "warrants") has been determined to SEK 0.24 . The exercise period for the warrants commences on 1 April 2025 and runs up to and including 15 April 2025 . The last day for trading in the warrants is 11 April 2025 ....

Immunovia provides further positive data from the VERIFI study of its next-generation pancreatic cancer test PR Newswire LUND, Sweden, March 24, 2025 LUND, Sweden , March 24, 2025 /PRNewswire/ - - Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced additional results from the successful VERIFI study of its next-generation pancreatic cancer test, strengthening the company's position as it prepares to launch the pancreatic cancer blood test...

Immunovia to host a webcast to share more data from the successful VERIFI clinical validation study PR Newswire LUND, Sweden, March 21, 2025 LUND, Sweden , March 21, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm) , the pancreatic cancer diagnostics company, published positive results from the VERIFI clinical validation of its next-generation test for pancreatic cancer on March 19, 2025 . As a follow up, Immunovia will host a webcast on Monday, March 24 at 3 pm CET . Jeff Borcherding ,...

Immunovia announces another successful clinical validation of its next-generation pancreatic cancer test PR Newswire LUND, Sweden, March 19, 2025 LUND, Sweden , March 19, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm) , the pancreatic cancer diagnostics company, today announced positive results from the VERIFI study, the second clinical validation study of its next-generation pancreatic cancer test. The study met its primary endpoint, with the test successfully detecting 77% of stage...

Immunovia's CLARITI study results selected for prestigious presentation at the world's largest gastroenterology conference PR Newswire LUND, Sweden, March 3, 2025 LUND, Sweden , March 3, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm) , the pancreatic cancer diagnostics company, today announces that the results of its CLARITI study have been selected for a distinguished plenary presentation at the upcoming Digestive Disease Week® (DDW) 2025 conference, taking place May 5, 2025 . The...

Immunovia Publishes Full Year Report for 2024 PR Newswire LUND, Sweden, Feb. 25, 2025 LUND, Sweden , Feb. 25, 2025 /PRNewswire/ -- October- December 2024 Net sales, which for the quarter only included royalties, amounted to 455 KSEK (155). Net earnings were 3,1 MSEK (-49,0) as a result of unrealized exchange rate effects due to a higher dollar rate on the transactions to finance operations in Immunovia Inc. Operating losses were -30,1 MSEK (-23,4). Earnings per share before and after dilution...

Immunovia initiates search for a new CFO to support commercialization in the USA PR Newswire LUND, Sweden, Feb. 21, 2025 LUND, Sweden , Feb. 21, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces that it will be hiring a new Chief Financial Officer (CFO) as its focus turns to the US market. As Immunovia transitions to commercializing its test in the second half of 2025, the company's financial leadership needs are changing. The...

Invitation to Immunovia's Q4 presentation PR Newswire LUND, Sweden, Feb. 21, 2025 LUND, Sweden , Feb. 21, 2025 /PRNewswire/ -- Immunovia will publish its full year 2024 results on February 25, 2025 at 8:30 am CET . Analysts, investors and media are invited to a webcast teleconference on the same day at 15:00 CET . The report together with the presentation slides will be available at www.immunovia.com . Jeff Borcherding, CEO and President, and Karin Almqvist Liwendahl, CFO, will present on...

Change in number of shares and votes in Immunovia AB (publ) PR Newswire LUND, Sweden, Jan. 31, 2025 LUND, Sweden , Jan. 31, 2025 /PRNewswire/ -- During January 2025 , the registered number of shares and votes in Immunovia AB (publ) ("Immunovia") has increased due exercise of warrants of series TO 2. As of 31 January 2025 , the registered number of shares and votes in Immunovia amounts to 261,908,863. For further information, please contact Jeff Borcherding , CEO [email protected]...

Change in number of shares and votes in Immunovia AB (publ) PR Newswire LUND, Sweden, Jan. 31, 2025 LUND, Sweden , Jan. 31, 2025 /PRNewswire/ -- During January 2025 , the registered number of shares and votes in Immunovia AB (publ) ("Immunovia") has increased due exercise of warrants of series TO 2. As of 31 January 2025 , the registered number of shares and votes in Immunovia amounts to 261,908,863. For further information, please contact: Jeff Borcherding , CEO [email protected]...

Immunovia AB announces outcome of exercise of warrants series TO 2 PR Newswire LUND, Sweden, Jan. 20, 2025 LUND, Sweden , Jan. 20, 2025 /PRNewswire/ -- The exercise period for warrants series TO 2 (the "Warrant Programme") in Immunovia AB (publ) ("Immunovia" or the "Company") ended on 16 January 2025 . A total of 92,197,387 warrants were exercised for the subscription of 92,197,387 new shares, corresponding to an exercise rate of approximately 74.1 percent. Thus, no guarantee commitments need to...

Immunovia AB announces outcome of exercise of warrants series TO 2 PR Newswire LUND, Sweden, Jan. 20, 2025 LUND, Sweden , Jan. 20, 2025 /PRNewswire/ -- The exercise period for warrants series TO 2 (the "Warrant Programme") in Immunovia AB (publ) ("Immunovia" or the "Company") ended on 16 January 2025 . A total of 92,197,387 warrants were exercised for the subscription of 92,197,387 new shares, corresponding to an exercise rate of approximately 74.1 percent. Thus, no guarantee commitments need to...

Immunovia AB (Publ) presents Nomination Committee PR Newswire LUND, Sweden, Jan. 8, 2025 LUND, Sweden , Jan. 8, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm) , the pancreatic cancer diagnostics company, today announced the appointment of the Company's Nomination Committee. According to the instructions for the Nomination Committee of Immunovia AB (Publ), the Nomination Committee shall consist of four members, of which three should be appointed by the Company's three largest...

Immunovia AB (Publ) presents Nomination Committee PR Newswire LUND, Sweden, Jan. 8, 2025 LUND, Sweden , Jan. 8, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm) , the pancreatic cancer diagnostics company, today announced the appointment of the Company's Nomination Committee. According to the instructions for the Nomination Committee of Immunovia AB (Publ), the Nomination Committee shall consist of four members, of which three should be appointed by the Company's three largest...

The exercise period for warrants of series TO 2 beings today: Immunovia AB PR Newswire LUND, Sweden, Jan. 2, 2025 LUND, Sweden , Jan. 2, 2025 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that today, 2 January 2025, the exercise period for warrants of series TO 2 in Immunovia AB (publ) ("Immunovia" or the "Company") (the "Warrant Programme") begins. The exercise period runs until 16 January 2025 . Summarized terms for the warrants of series TO 2 Structure :...

The exercise period for warrants of series TO 2 beings today: Immunovia AB PR Newswire LUND, Sweden, Jan. 2, 2025 LUND, Sweden , Jan. 2, 2025 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that today, 2 January 2025, the exercise period for warrants of series TO 2 in Immunovia AB (publ) ("Immunovia" or the "Company") (the "Warrant Programme") begins. The exercise period runs until 16 January 2025 . Summarized terms for the warrants of series TO 2 Structure :...

Immunovia announces determined exercise price for warrants series TO 2 and conditionally securing 65% of the warrant programme PR Newswire LUND, Sweden, Dec. 28, 2024 LUND, Sweden , Dec. 28, 2024 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that the exercise price for warrants series TO 2 (the "warrants") has been determined to SEK 0.46 . The exercise period for the warrants commences on 2 January 2025 and runs up to and including 16 January 2025 . The last...

Immunovia announces determined exercise price for warrants series TO 2 and conditionally securing 65% of the warrant programme PR Newswire LUND, Sweden, Dec. 28, 2024 LUND, Sweden , Dec. 28, 2024 /PRNewswire/ -- Immunovia AB (publ) ("Immunovia" or the "Company") hereby announces that the exercise price for warrants series TO 2 (the "warrants") has been determined to SEK 0.46 . The exercise period for the warrants commences on 2 January 2025 and runs up to and including 16 January 2025 . The last...